FY2024 EPS Estimates for 908 Devices Cut by Leerink Partnrs

908 Devices Inc. (NASDAQ:MASS - Free Report) - Equities researchers at Leerink Partnrs decreased their FY2024 earnings per share (EPS) estimates for shares of 908 Devices in a note issued to investors on Wednesday, November 13th. Leerink Partnrs analyst P. Souda now anticipates that the company will earn ($1.86) per share for the year, down from their previous estimate of ($1.12). Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for 908 Devices' current full-year earnings is ($1.21) per share. Leerink Partnrs also issued estimates for 908 Devices' Q4 2024 earnings at ($0.31) EPS, Q1 2025 earnings at ($0.36) EPS, Q2 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($1.23) EPS and FY2026 earnings at ($1.13) EPS.

Other equities research analysts have also issued reports about the company. Leerink Partners reiterated a "market perform" rating and issued a $4.00 price objective (down from $12.00) on shares of 908 Devices in a research note on Wednesday. Stifel Nicolaus lowered their price objective on 908 Devices from $17.00 to $6.00 and set a "buy" rating on the stock in a research note on Wednesday.

908 Devices Stock Performance

Shares of MASS stock traded up $0.01 during trading hours on Friday, hitting $2.39. The company had a trading volume of 414,801 shares, compared to its average volume of 205,849. 908 Devices has a 12 month low of $2.19 and a 12 month high of $12.51. The firm has a market capitalization of $83.23 million, a price-to-earnings ratio of -1.34 and a beta of 0.98. The firm's fifty day moving average is $3.44 and its 200 day moving average is $4.68.

Institutional Investors Weigh In On 908 Devices

A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its position in 908 Devices by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 1,751,102 shares of the company's stock worth $13,221,000 after acquiring an additional 6,772 shares during the last quarter. AWM Investment Company Inc. lifted its holdings in 908 Devices by 2.3% during the 1st quarter. AWM Investment Company Inc. now owns 668,526 shares of the company's stock worth $5,047,000 after buying an additional 15,058 shares in the last quarter. Millennium Management LLC lifted its holdings in 908 Devices by 35.5% during the 2nd quarter. Millennium Management LLC now owns 618,310 shares of the company's stock worth $3,184,000 after buying an additional 161,922 shares in the last quarter. State Street Corp lifted its holdings in 908 Devices by 1.2% during the 3rd quarter. State Street Corp now owns 479,044 shares of the company's stock worth $1,662,000 after buying an additional 5,704 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in 908 Devices by 88.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 245,176 shares of the company's stock worth $1,263,000 after buying an additional 114,987 shares in the last quarter. 88.06% of the stock is currently owned by institutional investors.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.